Top Markets
Coin of the day
Zenas BioPharma, Inc. Zenas BioPharma, Inc.

Zenas BioPharma, Inc.

ZBIO
Peringkat dalam Saham #6354
Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm,... Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm, concentrating on the creation and market introduction of innovative, immunology-based treatments. The company's primary investigational therapy is obexelimab, a distinctive bifunctional monoclonal antibody intended to address multiple diseases such as immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. Its developmental portfolio also features ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Established in 2019, the entity was formerly recognized as Zenas BioPharma (Cayman) Limited before adopting its current name, Zenas BioPharma, Inc., in August 2023. Its headquarters are located in Waltham, Massachusetts.
Harga Saham
$33.00
Kapitalisasi Pasar
$2.08B
Perubahan (1 hari)
-0.12%
Perubahan (1 tahun)
97.49%
Negara
US
Perdagangan Zenas BioPharma, Inc. (ZBIO)

Kategori

Riwayat harga saham Zenas BioPharma, Inc. (ZBIO)
Harga penutupan tertinggi: $31.75 pada 2026-08-01

Harga penutupan terendah: $17.96 pada 2024-09-01
Riwayat harga saham Zenas BioPharma, Inc. dari 2024 hingga 2026
Performa harga saham tahunan
Tahun Performa
2026 (TTM) -33.58%
2025 294.97%
2024 0.00%
Harga saham perusahaan atau pesaing serupa
Perusahaan Harga saham Perubahan 1th% Negara
$548.36 40.94%
US
$1.06K 49.46%
NL
$122.63 -12.65%
AU
$140.81 461.00%
US
$765.25 7.19%
CH